The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?

被引:16
作者
Camm, A. John [1 ]
机构
[1] Univ London St Georges Hosp, Div Clin Sci, Cranmer Terrace, London SW17 0RE, England
关键词
Atrial fibrillation; amiodarone; cardioversion; vernakalant;
D O I
10.2174/1573403X10666140513103709
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The sudden onset of atrial fibrillation (AF) is often associated with rapid irregular palpitations, chest pain, shortness of breath and considerable anxiety. If a patient presents shortly after the onset of the arrhythmia the physician may adopt initially an expectant "wait and see" policy, perhaps with the help of mild sedation and drug therapy to reduce the ventricular rate. If the arrhythmia does not terminate spontaneously and has been present for less than 24-48 hours restoration of sinus rhythm by cardioversion should be considered. This manuscript reviews the option of electrical cardioversion versus pharmacologic and the data for, the role of, and the status of vernakalant with respect to the latter.
引用
收藏
页码:309 / 314
页数:6
相关论文
共 21 条
[1]  
[Anonymous], 2010, EU SUMM PROD CHAR
[2]   Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation [J].
Bash, Lori D. ;
Buono, Jessica L. ;
Davies, Glenn M. ;
Martin, Amber ;
Fahrbach, Kyle ;
Phatak, Hemant ;
Avetisyan, Ruzan ;
Mwamburi, Mkaya .
CARDIOVASCULAR DRUGS AND THERAPY, 2012, 26 (02) :167-179
[3]   Vernakalant Selectively Prolongs Atrial Refractoriness With No Effect on Ventricular Refractoriness or Defibrillation Threshold in Pigs [J].
Bechard, Jeff ;
Gibson, John Ken ;
Killingsworth, Cheryl R. ;
Wheeler, Jeffery J. ;
Schneidkraut, Marlowe J. ;
Huang, Jian ;
Ideker, Raymond E. ;
McAfee, Donald A. .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2011, 57 (03) :302-307
[4]   Efficacy and Safety of Vernakalant in Recent-Onset Atrial Fibrillation After the European Medicines Agency Approval: Systematic Review and Meta-Analysis [J].
Buccelletti, Francesco ;
Iacomini, Paolo ;
Botta, Gianfranco ;
Marsiliani, Davide ;
Carroccia, Annarita ;
Silveri, Nicolo Gentiloni ;
Franceschi, Francesco .
JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (12) :1872-1878
[5]   Role of Late Sodium Channel Current Block in the Management of Atrial Fibrillation [J].
Burashnikov, Alexander ;
Antzelevitch, Charles .
CARDIOVASCULAR DRUGS AND THERAPY, 2013, 27 (01) :79-89
[6]   Rate-Dependent Effects of Vernakalant in the Isolated Non-Remodeled Canine Left Atria Are Primarily Due to Block of the Sodium Channel Comparison With Ranolazine and dl-Sotalol [J].
Burashnikov, Alexander ;
Pourrier, Marc ;
Gibson, John K. ;
Lynch, Joseph J. ;
Antzelevitch, Charles .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2012, 5 (02) :400-408
[7]   Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial [J].
Camm, A. John ;
Toft, Egon ;
Torp-Pedersen, Christian ;
Vijayaraman, Pugazhendhi ;
Juul-Moller, Steen ;
Ip, John ;
Beatch, Gregory N. ;
Dickinson, Garth ;
Wyse, D. George .
EUROPACE, 2012, 14 (06) :804-809
[8]   A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation [J].
Camm, A. John ;
Capucci, Alessandro ;
Hohnloser, Stefan H. ;
Torp-Pedersen, Christian ;
Van Gelder, Isabelle C. ;
Mangal, Brian ;
Beatch, Gregory .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (03) :313-321
[9]  
de Riva-Silva M, 2012, REV ESP CARDIOL, V65, P1062, DOI [10.1016/j.rec.2012.03.014, 10.1016/j.recesp.2012.03.015]
[10]   The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans [J].
Dorian, Paul ;
Pinter, Arnold ;
Mangat, Iqwal ;
Korley, Victoria ;
Cvitkovic, Suzan S. ;
Beatch, Gregory N. .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 50 (01) :35-40